Senti Biosciences (NASDAQ:SNTI) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Senti Biosciences (NASDAQ:SNTI) in a research report sent to investors on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $12.00 price target on the stock. HC Wainwright also issued estimates for Senti Biosciences’ Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($2.73) EPS, FY2026 earnings at ($1.29) EPS, FY2027 earnings at ($0.93) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at ($0.47) EPS.

Several other equities research analysts have also issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Senti Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, August 18th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Senti Biosciences in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Senti Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.67.

Senti Biosciences Trading Down 5.6%

SNTI stock opened at $2.18 on Tuesday. Senti Biosciences has a 1 year low of $1.26 and a 1 year high of $16.94. The company has a fifty day simple moving average of $1.54 and a 200 day simple moving average of $2.37. The firm has a market cap of $57.03 million, a PE ratio of -0.24 and a beta of 2.04.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.02. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $1.30 million. As a group, analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SNTI. Heights Capital Management Inc. bought a new position in shares of Senti Biosciences during the 1st quarter worth about $2,520,000. Nantahala Capital Management LLC bought a new position in shares of Senti Biosciences during the 1st quarter worth about $2,984,000. Geode Capital Management LLC increased its holdings in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the period. Finally, Armistice Capital LLC bought a new position in shares of Senti Biosciences during the 2nd quarter worth about $1,883,000. Institutional investors own 25.73% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.